[{"id":"3d58d724-7b7a-4521-94a7-0e3dc4880d42","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054374","created_at":"2021-09-23T17:53:02.260Z","updated_at":"2025-02-25T15:35:18.664Z","phase":"Phase 1/2","brief_title":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05054374","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124","tags":["HER-2 • ER • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2024-07-09"}]